Current Perspectives in Prostate Cancer Vaccines

被引：2
作者：
Arlen, Philip M. [1 ]
Gulley, James L. [1 ]
机构：
[1] NCI, Tumor Immunol & Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
来源：
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY | 2009年 / 9卷 / 10期
关键词：
Prostate cancer; immunotherapy; vaccine; cancer vaccine; clinical protocols; tumor-associated antigens; COLONY-STIMULATING FACTOR; REGULATORY T-CELLS; ANDROGEN-DEPRIVATION THERAPY; IMMUNE-RESPONSES; CELLULAR IMMUNOTHERAPY; IMMUNOLOGICAL RESPONSE; COMBINATION THERAPY; ANTITUMOR IMMUNITY; RADIATION-THERAPY; CTLA-4; BLOCKADE;
D O I：
10.2174/187152009789735062
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The use of vaccines as a potential therapeutic modality for the treatment of cancer has been extensively studied. Recent advances include identification and characterization of tumor-associated antigens, novel vaccine delivery systems, and the combination of vaccines with immune stimulants and other therapeutic modalities. Immunotherapy as a modality for treatment of prostate cancer has received significant attention. There are several characteristics of prostate cancer that make it an ideal target for immunotherapy. Prostate cancer's relative indolence allows sufficient time to generate immune responses, which may take weeks or months to mount. In addition, prostate cancer-associated antigens direct the immune response to prostate cancer cells, thus sparing normal vital tissue. This review focuses on promising new vaccines and novel perspectives in the treatment of prostate cancer.
引用
收藏
页码：1052 / 1057
页数：6
相关论文
共 68 条
  • [31] Distribution of CD4(+)CD25high regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancer
    Kawaida, H
    Kono, K
    Takahashi, A
    Sugai, H
    Mimura, K
    Miyagawa, N
    Omata, H
    Ooi, A
    Fujii, H
    [J]. JOURNAL OF SURGICAL RESEARCH, 2005, 124 (01) : 151 - 157
  • [32] Advances in specific immunotherapy for prostate cancer
    Kiessling, Andrea
    Fussel, Susanne
    Wehner, Rebekka
    Bachmann, Michael
    Wirth, Manfred P.
    Rieber, E. Peter
    Schmitz, Marc
    [J]. EUROPEAN UROLOGY, 2008, 53 (04) : 694 - 708
  • [33] Immature myeloid cells and cancer-associated immune suppression
    Kusmartsev, S
    Gabrilovich, DI
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2002, 51 (06) : 293 - 298
  • [34] Update on anti-CTLA-4 antibodies in clinical trials
    Langer, Lee F.
    Clay, Timothy M.
    Morse, Michael A.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2007, 7 (08) : 1245 - 1256
  • [35] Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant
    Lechleider, Robert J.
    Arlen, Philip M.
    Tsang, Kwong-Yok
    Steinberg, Seth M.
    Yokokawa, Junko
    Cereda, Vittore
    Camphausen, Kevin
    Schlom, Jeffrey
    Dahut, William L.
    Gulley, James L.
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (16) : 5284 - 5291
  • [36] IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity
    Litzinger, Mary T.
    Fernando, Romaine
    Curiel, Tyler J.
    Grosenbach, Douglas W.
    Schlom, Jeffrey
    Palena, Claudia
    [J]. BLOOD, 2007, 110 (09) : 3192 - 3201
  • [37] Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide
    Lutsiak, MEC
    Semnani, RT
    De Pascalis, R
    Kashmiri, SVS
    Schlom, J
    Sabzevari, H
    [J]. BLOOD, 2005, 105 (07) : 2862 - 2868
  • [38] Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy
    Madan, Ravi A.
    Gulley, James L.
    Schlom, Jeffrey
    Steinberg, Seth M.
    Liewehr, David J.
    Dahut, William L.
    Arlen, Philip M.
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (14) : 4526 - 4531
  • [39] Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas
    Marshall, JL
    Gulley, JL
    Arlen, PM
    Beetham, PK
    Tsang, KY
    Slack, R
    Hodge, JW
    Doren, S
    Grosenbach, DW
    Hwang, J
    Fox, E
    Odogwu, L
    Park, S
    Panicali, D
    Schlom, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (04) : 720 - 731
  • [40] T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer
    Mercader, M
    Bodner, BK
    Moser, MT
    Kwon, PS
    Park, ESY
    Manecke, RG
    Ellis, TM
    Wojcik, EM
    Yang, D
    Flanigan, RC
    Waters, WB
    Kast, WM
    Kwon, ED
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (25) : 14565 - 14570
1234567